Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;31(6):1269-1277.
doi: 10.1038/leu.2016.327. Epub 2016 Nov 14.

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

C Dafflon  1 , V J Craig  1 , H Méreau  2 , J Gräsel  1 , B Schacher Engstler  1 , G Hoffman  3 , F Nigsch  4 , S Gaulis  1 , L Barys  1 , M Ito  1 , J Aguadé-Gorgorió  5 , B Bornhauser  5 , J-P Bourquin  5 , A Proske  1 , C Stork-Fux  1 , M Murakami  1 , W R Sellers  6 , F Hofmann  1 , J Schwaller  2 , R Tiedt  1
Affiliations

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

C Dafflon et al. Leukemia. 2017 Jun.

Abstract

Chromosomal rearrangements of the mixed lineage leukemia (MLL/KMT2A) gene leading to oncogenic MLL-fusion proteins occur in ~10% of acute leukemias and are associated with poor clinical outcomes, emphasizing the need for new treatment modalities. Inhibition of the DOT1-like histone H3K79 methyltransferase (DOT1L) is a specific therapeutic approach for such leukemias that is currently being tested in clinical trials. However, in most MLL-rearranged leukemia models responses to DOT1L inhibitors are limited. Here, we performed deep-coverage short hairpin RNA sensitizer screens in DOT1L inhibitor-treated MLL-rearranged leukemia cell lines and discovered that targeting additional nodes of MLL complexes concomitantly with DOT1L inhibition bears great potential for superior therapeutic results. Most notably, combination of a DOT1L inhibitor with an inhibitor of the MLL-Menin interaction markedly enhanced induction of differentiation and cell killing in various MLL disease models including primary leukemia cells, while sparing normal hematopoiesis and leukemias without MLL rearrangements. Gene expression analysis on human and murine leukemic cells revealed that target genes of MLL-fusion proteins and MYC were suppressed more profoundly upon combination treatment. Our findings provide a strong rationale for a novel targeted combination therapy that is expected to improve therapeutic outcomes in patients with MLL-rearranged leukemia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nature. 2011 Oct 02;478(7370):529-33 - PubMed
    1. Cancer Res. 2005 Dec 15;65(24):11367-74 - PubMed
    1. Cell. 2014 Oct 23;159(3):558-71 - PubMed
    1. Mol Syst Biol. 2007;3:80 - PubMed
    1. Trends Mol Med. 2004 Oct;10(10):500-7 - PubMed

MeSH terms